Investor Relations

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies.

Investor Presentation

Download PDF

Recent News

Investor Alerts

Aug 30, 2024

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 29, 2024, the...

Aug 26, 2024

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the Morgan...

Aug 23, 2024

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 19, 2024, the...

All Releases

Events

Morgan Stanley 22nd Annual Global Healthcare Conference

Wednesday, September 4, 2024

5:45pm EDT

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Judah Frommer, Executive Director, Senior Equity Research Analyst

IDEAYA Biosciences Phase 2 Clinical Data Update for IDE397 in MTAP-Deletion Urothelial and NSCLC

Monday, July 8, 2024

8:00am EDT

A replay is available through the following link:
https://lifescievents.com/event/ideaya-2/

All Events

Investor Resources